Management of ‘no‐reflow’ complicating reperfusion therapy

References

• Kloner R. A. Foreword—No‐reflow: Basic science to a clinical phenomenon. Basic Res Cardiol 2006; 101: 357–8
   Google Scholar
• Eeckhout E., Kern M. J. The coronary no‐reflow phenomenon: a review of mechanisms and therapies. Eur Heart J 2001; 22: 729–39
   PubMed Web of Science ®Google Scholar
• Takahashi T., Anzai T., Yoshikawa T., Asakura Y., Ishikawa S., Mitamura H., et al. Absence of preinfarction angina is associated with a risk of no‐reflow phenomenon after primary coronary angioplasty for a first anterior wall acute myocardial infarction. Int J Cardiol 2000; 75: 253–60
   Google Scholar
• Abbo K. M., Dooris M., Glazier S., O'Neill W. W., Byrd D., Grines C. L., et al. Features and outcome of no‐reflow after percutaneous coronary intervention. Am J Cardiol 1995; 75: 778–82
   PubMed Web of Science ®Google Scholar
• Piana R. N., Paik G. Y., Moscucci M., Cohen D. J., Gibson C. M., Kugelmass A. D., et al. Incidence and treatment of ‘no‐reflow’ after percutaneous coronary intervention. Circulation 1994; 89: 2514–8
   PubMed Web of Science ®Google Scholar
• Resnic F. S., Wainstein M., Lee M. K., Behrendt D., Wainstein R. V., Ohno‐Machado L., et al. No‐reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J 2003; 145: 42–6
   PubMed Web of Science ®Google Scholar
• Tsubokawa A., Ueda K., Sakamoto H., Iwase T., Tamaki S. Effect of intracoronary nicorandil administration on preventing no‐reflow/slow flow phenomenon during rotational atherectomy. Circ J 2002; 66: 1119–23
   PubMed Web of Science ®Google Scholar
• Galiuto L., Lombardo A., Maseri A., Santoro L., Porto I., Cianflone D., et al. Temporal evolution and functional outcome of no reflow: sustained and spontaneously reversible patterns following successful coronary recanalisation. Heart 2003; 89: 731–7
   PubMed Web of Science ®Google Scholar
• Lee C. H., Wong H. B., Tan H. C., Zhang J. J., Teo S. G., Ong H. Y., et al. Impact of reversibility of no reflow phenomenon on 30‐day mortality following percutaneous revascularization for acute myocardial infarction‐insights from a 1,328 patient registry. J Interv Cardiol 2005; 18: 261–6
   PubMedGoogle Scholar
• Galiuto L. Optimal therapeutic strategies in the setting of post‐infarct no reflow: the need for a pathogenetic classification. Heart 2004; 90: 123–5
   Google Scholar
• Rezkalla S. H., Kloner R. A. No‐reflow phenomenon. Circulation 2002; 105: 656–62
   PubMed Web of Science ®Google Scholar
• Gibson C. M., Cannon C. P., Murphy S. A., Ryan K. A., Mesley R., Marble S. J., et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000; 101: 125–30
   PubMed Web of Science ®Google Scholar
• Klein L. W., Kern M. J., Berger P., Sanborn T., Block P., Babb J., et al. Society of cardiac angiography and interventions: suggested management of the no‐reflow phenomenon in the cardiac catheterization laboratory. Catheter Cardiovasc Interv 2003; 60: 194–201
   PubMed Web of Science ®Google Scholar
• Chen J. P. Dual lumen catheters: more than just aspiration. J Invasive Cardiol 2006; 18: 346
   Google Scholar
• Wilson R. F., Laxson D. D., Lesser J. R., White C. W. Intense microvascular constriction after angioplasty of acute thrombotic coronary arterial lesions. Lancet 1989; 1: 807–11
   PubMed Web of Science ®Google Scholar
• Kern M. J. Adenosine boluses: a cure for ‘no‐reflow’?. Cathet Cardiovasc Diagn 1998; 45: 366–7
   Google Scholar
• Granger C. B. Adenosine for myocardial protection in acute myocardial infarction. Am J Cardiol 1997; 79: 44–8
   PubMed Web of Science ®Google Scholar
• Assali A. R., Sdringola S., Ghani M., Denkats A. E., Yepes A., Hanna G. P., et al. Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of ‘no reflow’ phenomenon. Catheter Cardiovasc Interv 2000; 51: 27–31
   PubMed Web of Science ®Google Scholar
• Micari A., Belcik T. A., Balcells E. A., Powers E., Wei K., Kaul S., et al. Improvement in microvascular reflow and reduction of infarct size with adenosine in patients undergoing primary coronary stenting. Am J Cardiol 2005; 96: 1410–5
   PubMed Web of Science ®Google Scholar
• Ross A. M., Gibbons R. J., Stone G. W., Kloner R. A., Alexander R. W. A randomized, double‐blinded, placebo‐controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD‐II). J Am Coll Cardiol 2005; 45: 1775–80
   PubMed Web of Science ®Google Scholar
• Kloner R. A., Forman M. B., Gibbons R. J., Ross A. M., Alexander R. W., Stone G. W. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD‐2 trial. Eur Heart J 2006; 27: 2400–5
   PubMed Web of Science ®Google Scholar
• Sdringola S., Assali A., Ghani M., Yepes A., Rosales O., Schroth G. W., et al. Adenosine use during aortocoronary vein graft interventions reverses but does not prevent the slow‐no reflow phenomenon. Catheter Cardiovasc Interv 2000; 51: 394–9
   PubMed Web of Science ®Google Scholar
• Michaels A. D., Appleby M., Otten M. H., Dauterman K., Ports T. A., Chou T. M., et al. Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results of the randomized, controlled vasodilator prevention on no‐reflow (VAPOR) trial. J Invasive Cardiol 2002; 14: 299–302
   PubMedGoogle Scholar
• Werner G. S., Lang K., Kuehnert H., Figulla H. R. Intracoronary verapamil for reversal of no‐reflow during coronary angioplasty for acute myocardial infarction. Catheter Cardiovasc Interv 2002; 57: 444–51
   PubMed Web of Science ®Google Scholar
• Taniyama Y., Ito H., Morishita R., Ogihara T. Potential of microvascular reperfusion with adjunctive pharmacological intervention: its impact on myocardial perfusion and functional outcomes in patients with acute myocardial infarction. Drugs 2001; 61: 437–41
   Google Scholar
• Hillegass W. B., Dean N. A., Liao L., Rhinehart R. G., Myers P. R. Treatment of no‐reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience. J Am Coll Cardiol 2001; 37: 1335–43
   PubMed Web of Science ®Google Scholar
• Barcin C., Denktas A. E., Lennon R. J., Hammes L., Higano S. T., Holmes D. R., Jr., et al. Comparison of combination therapy of adenosine and nitroprusside with adenosine alone in the treatment of angiographic no‐reflow phenomenon. Catheter Cardiovasc Interv 2004; 61: 484–91
   Google Scholar
• Pasceri V., Pristipino C., Pelliccia F., Granatelli A., Speciale G., Roncella A., et al. Effects of the nitric oxide donor nitroprusside on no‐reflow phenomenon during coronary interventions for acute myocardial infarction. Am J Cardiol 2005; 95: 1358–61
   PubMed Web of Science ®Google Scholar
• Amit G., Cafri C., Yaroslavtsev S., Fuchs S., Paltiel O., Abu‐Ful A., et al. Intracoronary nitroprusside for the prevention of the no‐reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double‐blind, placebo‐controlled clinical trial. Am Heart J 2006; 152: 887–914
   PubMedGoogle Scholar
• Wohrle J., Grebe O. C., Nusser T., Al Khayer E., Schaible S., Kochs M., et al. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty. Circulation 2003; 107: 1840–3
   PubMed Web of Science ®Google Scholar
• Roffi M., Mukherjee D., Chew D. P., Bhatt D. L., Cho L., Robbins M. A., et al. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials. Circulation 2002; 106: 3063–7
   PubMed Web of Science ®Google Scholar
• Jonas M., Stone G. W., Mehran R., Hermiller J., Feldman R., Herrmann H. C., et al. Platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment during saphenous vein graft stenting: differential effects after randomization to occlusion or filter‐based embolic protection. Eur Heart J 2006; 27: 920–8
   PubMedGoogle Scholar
• Skelding K. A., Goldstein J. A., Mehta L., Pica M. C., O'Neill W. W. Resolution of refractory no‐reflow with intracoronary epinephrine. Catheter Cardiovasc Interv 2002; 57: 305–9
   PubMed Web of Science ®Google Scholar
• Baim D. S., Wahr D., George B., Leon M. B., Greenberg J., Cutlip D. E., et al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto‐coronary bypass grafts. Circulation 2002; 105: 1285–90
   PubMed Web of Science ®Google Scholar
• Halkin A., Masud A. Z., Rogers C., Hermiller J., Feldman R., Hall P., et al. Six‐month outcomes after percutaneous intervention for lesions in aortocoronary saphenous vein grafts using distal protection devices: results from the FIRE trial. Am Heart J 2006; 151: 915–7
   Google Scholar
• Silva‐Orrego P., Colombo P., Bigi R., Gregori D., Delgado A., Salvade P., et al. Thrombus aspiration before primary angioplasty improves myocardial reperfusion in acute myocardial infarction: the DEAR‐MI (Dethrombosis to Enhance Acute Reperfusion in Myocardial Infarction) study. J Am Coll Cardiol 2006; 48: 1552–9
   Web of Science ®Google Scholar
• Cura F. A., Escudero A. G., Berrocal D., Mendiz O., Trivi M. S., Fernandez J., et al. Protection of Distal Embolization in High‐Risk Patients with Acute ST‐Segment Elevation Myocardial Infarction (PREMIAR). Am J Cardiol 2007; 99: 357–63
   PubMed Web of Science ®Google Scholar
• Stone G. W., Webb J., Cox D. A., Brodie B. R., Qureshi M., Kalynych A., et al. Distal microcirculatory protection during percutaneous coronary intervention in acute ST‐segment elevation myocardial infarction: a randomized controlled trial. JAMA 2005; 293: 1063–72
   PubMed Web of Science ®Google Scholar
• Limbruno U., De Caterina R. EMERALD, AIMI, and PROMISE: Is there still a potential for embolic protection in primary PCI?. Eur Heart J 2006; 27: 1139–45
   Google Scholar
• Antoniucci D. Rheolytic Thrombectomy in acute myocardial infarction: The Florence experience and objectives of the multicenter randomized jetstent trial. J Invasive Cardiol 2006; 18: 32C–4C
   Google Scholar
• Kaplan B. M., Benzuly K. H., Kinn J. W., Bowers T. R., Tilli F. V., Grines C. L., et al. Treatment of no‐reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin. Cathet Cardiovasc Diagn 1996; 39: 113–8
   PubMedGoogle Scholar
• Vijayalakshmi K., Whittaker V. J., Kunadian B., Graham J., Wright R. A., Hall J. A., et al. Prospective, randomised, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes. Heart 2006; 92: 1278–84
   PubMed Web of Science ®Google Scholar
• Hendler A., Aronovich A., Kaluski E., Zyssman I., Gurevich Y., Blatt A. Optimization of myocardial perfusion after primary coronary angioplasty following an acute myocardial infarction. Beyond TIMI 3 flow. J Invasive Cardiol 2006; 18: 32–6
   Google Scholar
• Ota S., Nishikawa H., Takeuchi M., Nakajima K., Nakamura T., Okamoto S., et al. Impact of nicorandil to prevent reperfusion injury in patients with acute myocardial infarction: Sigmart Multicenter Angioplasty Revascularization Trial (SMART). Circ J 2006; 70: 1099–104
   PubMed Web of Science ®Google Scholar
• Petronio A. S., De Carlo M., Ciabatti N., Amoroso G., Limbruno U., Palagi C. Left ventricular remodeling after primary coronary angioplasty in patients treated with abciximab or intracoronary adenosine. Am Heart J 2005; 150: 1015
   PubMed Web of Science ®Google Scholar
• Wang H. J., Lo P. H., Lin J. J., Lee H., Hung J. S. Treatment of slow/no‐reflow phenomenon with intracoronary nitroprusside injection in primary coronary intervention for acute myocardial infarction. Catheter Cardiovasc Interv 2004; 63: 171–6
   PubMed Web of Science ®Google Scholar
• Huang R. I., Patel P., Walinsky P., Fischman D. L., Ogilby J. D., Awar M., et al. Efficacy of intracoronary nicardipine in the treatment of no‐reflow during percutaneous coronary intervention. Catheter Cardiovasc Interv 2006; 68: 671–6
   PubMed Web of Science ®Google Scholar